Clinical oversight is not an add on
Upgrades Health · July 8, 2026 · 5 minute read
There is a version of the GLP-1 benefit that treats medicine as logistics. Verify eligibility, process payment, ship product, repeat monthly. Care, in that version, is a checkbox in the add ons column, provided by a third party, priced separately, and easy to decline. We think that version has the structure exactly backward.
What GLP-1 therapy actually involves
These medications are not a one time transaction. Therapy runs for months or years. Doses change over time. Side effects are common early and need managing, or people quit in the first stretch and the employer pays for a benefit that produced nothing. Real questions come up: what to do around a surgery, how to handle a pause, whether a plateau means adjusting or stopping. Every one of those moments needs clinical judgment from someone who knows the patient.
A checkout program has no one in that seat. The prescriber who wrote the initial script may never see the patient again. The optional monitoring vendor, if the employer bought it, has a portal and a queue. The employee stands in the gap, and the gap is where therapy fails.
The medication is the easy part. The care is the product.
Why the gap lands on the employer
Employers do not carve out GLP-1s for fun. They do it to control a cost that was eating the plan. But cost control assumes the therapy works, and unmanaged therapy quietly fails in ways a spreadsheet takes a year to notice. Employees who stop in month two still generated fills. Employees on the wrong dose generate fills indefinitely. A program without an accountable clinician does not just risk worse outcomes. It spends the employer's money less well, fill after fill.
There is also the plainer risk. When something goes wrong for an employee and the employer asks who was responsible, a stack of vendor contracts that all point at each other is a bad answer. One clinical relationship with one accountable program is a good one.
What built in oversight looks like
Built in is a structural claim, not a marketing one. It means the clinical work is inside the program's core price and core operations, not an attachment. In practice, four things:
- Evaluation before prescription. A licensed clinician makes an individual determination for every employee, and the program is willing to say no.
- A standing clinical relationship. The same clinical team follows the employee through therapy, so month six conversations happen with context, not a cold file.
- Scheduled monitoring. Check ins happen on a protocol, not only when the employee complains. Dose management is proactive.
- An owned outcome. When therapy should end, the program says so, even though ending therapy ends fills. A vendor whose revenue depends on refills and whose care is optional has no reason to ever say stop.
The test worth applying
If you are evaluating any GLP-1 program, ours included, apply one test: could the program describe its clinical operation with the medication removed? A real clinical program still has something to describe. An evaluation process, a monitoring protocol, an escalation path, accountable clinicians. A checkout program with the checkout removed is an empty page.
We built Upgrades Health so the clinical layer is the program. The pricing structure matters, and we are proud of it, but it exists to make the care affordable, not the other way around. That order of operations is the whole company. You can see how the pieces fit on the how it works page.
